← Back to Search

Other

PF-07275315 in Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants with a body mass index (BMI) of 17.5 to 32 kg/m2 and a total body weight >50 kg (110 lb)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-561 days
Awards & highlights

Study Summary

This trial is testing a new drug to see how safe and tolerable it is, and how it is metabolized and eliminated by the body.

Who is the study for?
Healthy individuals who have a BMI of 17.5 to 32 and weigh over 110 pounds can join this study. They must be free from significant recent trauma, major surgeries, TB, HIV, hepatitis B or C, and cannot have current or past malignancies except for certain skin cancers or cervical carcinoma in situ.Check my eligibility
What is being tested?
The trial is testing PF-07275315's safety and effects compared to a placebo in healthy people. Participants will receive either the drug or placebo through an IV infusion across different groups with increasing doses deemed safe by the sponsor.See study design
What are the potential side effects?
Since PF-07275315 is being tested for the first time in humans, potential side effects are unknown but will be closely monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is between 17.5 and 32, and I weigh more than 110 pounds.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-561 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-561 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with Adverse Events (AEs)
Number of participants with Serious AEs (SAEs)
Number of participants with clinically meaningful change from baseline in ECG parameters
+2 more
Secondary outcome measures
AUC of PF-07275315 serum concentration time-profile over the dosing interval of 2 weeks or 336 hours
Area under the curve (AUC) of PF-07275315 serum concentration time-profile from time zero extrapolated to infinite time
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of PF-07275315
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ActiveExperimental Treatment1 Intervention
PF-07275315
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,567 Previous Clinical Trials
10,911,808 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,474 Previous Clinical Trials
8,092,976 Total Patients Enrolled

Media Library

PF-07275315 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05411588 — Phase 1
Healthy Subjects Research Study Groups: Active, Placebo
Healthy Subjects Clinical Trial 2023: PF-07275315 Highlights & Side Effects. Trial Name: NCT05411588 — Phase 1
PF-07275315 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05411588 — Phase 1
Healthy Subjects Patient Testimony for trial: Trial Name: NCT05411588 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What characteristics should an ideal candidate for this trial possess?

"The trial is seeking 89 participants meeting the healthy subject criteria and aged between 18 to 65."

Answered by AI

What is the maximum allowable number of participants in this research endeavor?

"That is correct. According to the information hosted on clinicaltrials.gov, this investigation was initially posted on June 9th 2022 and was updated most recently in October 24th 2022; it is looking for 89 participants across 3 medical centres."

Answered by AI

What potential hazards are posed by PF-07275315 on human health?

"Taking into consideration the preliminary nature of this trial, we have assigned a score of 1 to PF-07275315's safety profile as there is limited clinical data that supports its efficacy and security."

Answered by AI

What conclusions are expected to be reached through this experiment?

"According to the trial's sponsor, Pfizer, this study will measure primary outcome data over a baseline of 561 days. This includes tracking changes in vital signs as well as secondary outcomes such as AUCinf (Area under the curve extrapolated to infinite time), ADA incidence rate (Antidrug antibodies development against PF-07275315) and AUClast (Area under the plasma concentration-time curve from time 0 to last quantifiable concentration)."

Answered by AI

Is enrollment still possible for this scientific investigation?

"Per information on clinicaltrials.gov, recruiting efforts for this medical trial are ongoing; the initial post was made June 9th 2022 and the details were revised October 24th 2022."

Answered by AI

Can individuals younger than 25 years old enroll in this medical experiment?

"To be eligible for this particular trial, applicants must fall between the age brackets of 18 and 65. Additionally, there are 50 trials that cater to people under 18 and 373 studies open to those over 65."

Answered by AI

Who else is applying?

What state do they live in?
New York
California
What site did they apply to?
Other
Qps-Mra, Llc
Orange County Research Center
New Haven Clinical Research Unit
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

To help be a part of something that’ll help someone else.
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Orange County Research Center: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People
2022. "A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05411588.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top